PL EN


Preferences help
enabled [disable] Abstract
Number of results
2014 | 12 | 2 | 140-154
Article title

Ograniczenia w leczeniu chirurgicznym raka jajnika

Content
Title variants
EN
Limitations in the treatment of ovarian carcinoma
Languages of publication
EN PL
Abstracts
EN
Removal of all foci of ovarian carcinoma during the first surgery considerably improves overall survival. Obtaining complete cytoreduction is not, however, possible in each case. When the procedure is performed in a referral center, complete cytoreduction is obtained in as many as 75–90% of patients. A lot of recent studies indicate that experience of the physician who performs the first procedure affects the degree of cytoreduction. Moreover, the experience of the center in which treatment is started also influences overall survival. Therefore, one might contribute to the improvement of the therapy outcome by refining one’s surgical skills. The experience of a surgeon is essential in resecting metastatic foci in sites such as the hepatoduodenal ligament, omental foramen, splenic recess of the peritoneum, superior omental recess, splenic hilum, tail of the pancreas as well as areas of the diaphragmatic and renal vessels. For a procedure to be effective, it must involve the entire peritoneum with all its recesses. The essential elements of the procedure which decide about the degree of cytoreduction are: 1) removing the rectum and peritoneum of the lower recess (modified posterior exenteration); 2) resection of the ovarian vessels and para-aortic lymphadenectomy; 3) removing the peritoneum of the diaphragm and partial resection of the diaphragm; 4) fragmentary resection of the gastrointestinal tract; 5) splenectomy with resection of foci in the lesser sac. The paper presents anatomic limitations that affect surgical treatment of ovarian carcinoma in these regions.
PL
Usunięcie wszystkich ognisk raka jajnika w czasie pierwszej operacji wydłuża znamiennie całkowite przeżycie. Doprowadzenie do całkowitej cytoredukcji nie jest jednak możliwe w każdym przypadku. Gdy zabieg przeprowadza się w ośrodku referencyjnym, całkowita cytoredukcja osiągana jest nawet u 75–90% operowanych chorych. Wiele ostatnich badań wskazuje, że o stopniu cytoredukcji decyduje doświadczenie lekarza, który wykonał pierwszą operację. Istotne dla całkowitego przeżycia jest także doświadczenie ośrodka, w którym rozpoczyna się leczenie. Dlatego dbając o warsztat chirurgiczny, można przyczynić się do poprawy wyników terapii. Doświadczenie chirurga jest niezbędne w resekcji ognisk przerzutowych w takich miejscach, jak więzadło wątrobowo-dwunastnicze, otwór sieciowy, zachyłek śledzionowy otrzewnej, zachyłek górny torby sieciowej, wnęka śledziony, ogon trzustki, okolice naczyń przeponowych i naczyń nerkowych. Aby zabieg zakończył się sukcesem, powinien dotyczyć całej otrzewnej i wszystkich jej zachyłków. Kluczowe elementy tej operacji, decydujące o stopniu cytoredukcji, to: 1) usunięcie odbytnicy i otrzewnej zachyłka dolnego (zmodyfikowane wytrzewienie tylne); 2) resekcja naczyń jajnikowych i limfadenektomia okołoaortalna; 3) usunięcie otrzewnej z przepony i częściowe resekcje przepony; 4) resekcje odcinkowe przewodu pokarmowego; 5) splenektomia wraz z resekcją ognisk z torby sieciowej. W pracy przedstawiono anatomiczne ograniczenia wpływające na przebieg leczenia chirurgicznego raka jajnika w tych obszarach.
Discipline
Publisher

Year
Volume
12
Issue
2
Pages
140-154
Physical description
Contributors
  • Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek
  • Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek
  • Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie. Kierownik Kliniki: prof. dr hab. n. med. Beata Śpiewankiewicz
  • Klinika Chirurgii Endoskopowej i Nowotworów Tkanek Miekkich UJCM w Krakowie. Kierownik Kliniki: prof. dr hab. n. med. Andrzej Budzyński
author
  • Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek
author
  • Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie. Kierownik Kliniki: prof. dr hab. n. med. Krzysztof Urbański
author
  • Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek. Klinika Ginekologii Onkologicznej, Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie, Oddział w Krakowie. Kierownik Kliniki: prof. dr hab. n. med. Krzysztof Urbański
  • Oddział Kliniczny Ginekologii Onkologicznej, Centrum Onkologii im. prof. Franciszka Łukaszczyka w Bydgoszczy, ul. Romanowskiej 2, 85-796 Bydgoszcz, tel.: +48 52 374 33 99, +48 52 374 38 74. Kierownik Oddziału: prof. dr hab. n. med. Łukasz Wicherek, mowicher@cyf-kr.edu.pl
References
  • 1. Bristow R.E., Puri I., Chi D.S.: Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol. Oncol. 2009; 112: 265–274.
  • 2. Bristow R.E.: Advanced cytoreductive surgery in gynecologic oncology. Gynecol. Oncol. 2009; 114 (supl.): S1–S2.
  • 3. Bristow R.E.: Predicting “unresectable” ovarian cancer: taking aim at a moving target. Gynecol. Oncol. 2006; 100: 449–450.
  • 4. Bristow R.E.: Predicting surgical outcome for advanced ovarian cancer, surgical standards of care, and the concept of kaizen. Gynecol. Oncol. 2009; 112: 1–3.
  • 5. Bristow R.E., Chang J., Ziogas A. i wsp.: High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol. Oncol. 2014; 132: 403–410.
  • 6. Bristow R.E., Palis B.E., Chi D.S., Cliby W.A.: The National Cancer Database report on advanced-stage epithelial ovarian cancer: impact of hospital surgical case volume on overall survival and surgical treatment paradigm. Gynecol. Oncol. 2010; 118: 262–267.
  • 7. du Bois A., Reuss A., Pujade-Lauraine E. i wsp.: Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244.
  • 8. Pathiraja P.N., Garruto-Campanile R., Tozzi R.: Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer. Int. J. Surg. Oncol. 2013; 2013: 876150.
  • 9. Gonzalez Bayon L., Steiner M.A., Vasquez Jimenez W. i wsp.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur. J. Surg. Oncol. 2013; 39: 1109–1115.
  • 10. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y. i wsp.: The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol. Oncol. 2006; 103: 1083–1090.
  • 11. du Bois A., Quinn M., Thigpen T. i wsp.; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC: 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 2005; 16 (supl. 8): viii7–viii12.
  • 12. Cascales Campos P., Gil J., Parrilla P.: Morbidity and mortality outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary and recurrent advanced ovarian cancer. Eur. J. Surg. Oncol. 2014; 40: 970–975.
  • 13. Aletti G.D., Eisenhauer E.L., Santillan A. i wsp.: Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol. Oncol. 2011; 120: 23–28.
  • 14. Bakrin N., Bereder J.M., Decullier E. i wsp.; FROGHI (French Oncologic and Gynecologic HIPEC) Group: Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur. J. Surg. Oncol. 2013; 39: 1435–1443.
  • 15. Chang S.J., Bristow R.E., Ryu H.S.: Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann. Surg. Oncol. 2012; 19: 4059–4067.
  • 16. Mahner S., Eulenburg C., Staehle A. i wsp.: Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur. J. Cancer 2013; 49: 142–149.
  • 17. Harter P., Beutel B., Alesina P.F. i wsp.: Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer. Gynecol. Oncol. 2014; 132: 537–541.
  • 18. Wicherek Ł., Kuśnierz B., Śpiewankiewicz B.: Przydatność zmodyfikowanego wytrzewienia tylnego w leczeniu raka jajnika. Curr. Gynecol. Oncol. 2013; 11: 125–136.
  • 19. Basta T., Bidziński M., Classe J.M. i wsp.: How can cytoreductive surgery (CRS) and hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) be implemented in ovarian cancer therapy in Poland? A report from the 1st Kujawsko-Pomorski Days of Cytoreductive Surgery. Arch. Perinat. Med. 2013; 19: 173–178.
  • 20. Wicherek Ł., Rajs T., Koper K. i wsp.: Surgical treatment of advanced ovarian cancer. Curr. Gynecol. Oncol. 2012; 10: 88–100.
  • 21. Chang S.J., Bristow R.E.: Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining “optimal” residual disease. Gynecol. Oncol. 2012 125: 483–492.
  • 22. Rungruang B., Miller A., Richard S.D. i wsp.: Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease? A Gynecologic Oncology Group study. Gynecol. Oncol. 2012; 124: 53–58.
  • 23. du Bois A., Reuss A., Harter P. i wsp.; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom; Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens: Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J. Clin. Oncol. 2010; 28: 1733–1739.
  • 24. Chang S.J., Bristow R.E., Ryu H.S.: Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer. Gynecol. Oncol. 2012; 126: 381–386.
  • 25. Benedetti-Panici P., Maneschi F., Scambia G.: The pelvic retroperitoneal approach in the treatment of advanced ovarian carcinoma. Obstet. Gynecol. 1996; 87: 532–538.
  • 26. Chang S.J., Bristow R.E., Ryu H.S.: Analysis of para-aortic lymphadenectomy up to the level of the renal vessels in apparent early-stage ovarian cancer. J. Gynecol. Oncol. 2013; 24: 29–36.
  • 27. Deraco M., Virzì S., Iusco D.R. i wsp.: Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG 2012; 119: 800–809.
  • 28. Deraco M., Baratti D., Hutanu I. i wsp.: The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 2013; 20: 1093–1100.
  • 29. Deraco M., Baratti D., Laterza B. i wsp.: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur. J. Surg. Oncol. 2011; 37: 4–9.
  • 30. Pomel C., Jeyarajah A., Oram D. i wsp.: Cytoreductive surgery in ovarian cancer. Cancer Imaging 2007; 7: 210–215.
  • 31. Fagotti A., Costantini B., Vizzielli G. i wsp.: HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol. Oncol. 2011; 122: 221–225.
  • 32. Teo M.C.: Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer. Curr. Opin. Obstet. Gynecol. 2014; 26: 3–8.
  • 33. Pomel C., Ferron G., Lorimier G. i wsp.: Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur. J. Surg. Oncol. 2010; 36: 589–593.
  • 34. Classe J.M., Jaffre I., Frenel J.S. i wsp.: Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: a retrospective study of 108 cases. Eur. J. Surg. Oncol. 2011; 37: 971–977.
  • 35. Di Giorgio A., Naticchioni E., Biacchi D. i wsp.: Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 2008; 113: 315–325.
  • 36. Chan D.L., Morris D.L., Rao A., Chua T.C.: Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag. Res. 2012; 4: 413–422.
  • 37. da Silva R.G., Sugarbaker P.H.: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. J. Am. Coll. Surg. 2006; 203: 878–886.
  • 38. Sugarbaker P.H., Chang D.: Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann. Surg. Oncol. 1999; 6: 727–731.
  • 39. Sugarbaker P.H.: Management of peritoneal-surface malignancy: the surgeon’s role. Langenbecks Arch. Surg. 1999; 384: 576–587.
  • 40. Sugarbaker P.H.: Avoiding a throwback to the past. J. Clin. Oncol. 2013; 31: 396–397.
  • 41. Adams S.F., Levine D.A., Cadungog M.G. i wsp.: Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115: 2891–2902.
  • 42. Martinez A., Pomel C., Mery E. i wsp.: Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol. Oncol. 2011; 121: 258–263.
  • 43. Houvenaeghel G., Gutowski M., Buttarelli M. i wsp.: Modified posterior pelvic exenteration for ovarian cancer. Int. J. Gynecol. Cancer 2009; 19: 968–973.
  • 44. Mourton S.M., Temple L.K., Abu-Rustum N.R. i wsp.: Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol. Oncol. 2005; 99: 608–614.
  • 45. Scarabelli C., Gallo A., Franceschi S.: Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 2000; 88: 389–397.
  • 46. Scholz H.S., Tasdemir H., Hunlich T. i wsp.: Multivisceral cytoreductive surgery in FIGO stages IIIC and IV epithelial ovarian cancer: results and 5-year follow-up. Gynecol. Oncol. 2007; 106: 591–595.
  • 47. Spirtos N.M., Eisenkop S.M., Schlaerth J.B., Ballon S.C.: Second-look laparotomy after modified posterior exenteration: patterns of persistence and recurrence in patients with stage III and stage IV ovarian cancer. Am. J. Obstet. Gynecol. 2000; 182: 1321–1327.
  • 48. Rohen J.W., Yokochi C., Lütjen-Drecoll E.: Atlas anatomii: fotograficzne studium ciała człowieka. Wydawnictwo Lekarskie PZWL, Warszawa 2011.
  • 49. Raspagliesi F., Ditto A., Martinelli F. i wsp.: Advanced ovarian cancer: omental bursa, lesser omentum, celiac, portal and triad nodes spread as cause of inaccurate evaluation of residual tumor. Gynecol. Oncol. 2013; 129: 92–96.
  • 50. Eisenkop S.M., Nalick R.H., Teng N.N.: Modified posterior exenteration for ovarian cancer. Obstet. Gynecol. 1991; 78: 879–885.
  • 51. Eisenkop S.M., Spirtos N.M., Friedman R.L.: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol. Oncol. 2003; 90: 390–396.
  • 52. Morice P., Dubernard G., Rey A. i wsp.: Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J. Am. Coll. Surg. 2003; 197: 955–963.
  • 53. Phippen N.T., Barnett J.C., Lowery W.J. i wsp.: Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility. Gynecol. Oncol. 2013; 131: 158–162.
  • 54. Kusamura S., Baratti D., Hutanu I. i wsp.: The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg. Oncol. Clin. N. Am. 2012; 21: 559–576.
Document Type
article
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.psjd-0483d374-8a09-40cc-b9cd-71cf0ebb65c6
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.